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The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study demonstrated the superiority of a losartan-based regimen over atenolol-based regimen for reduction of cardiovascular (CV) morbidity and mortality. The primary endpoint was a composite of cardiovascular death, myocardial infarction, and stroke. New-onset diabetes (NOD) was a pre-specified secondary endpoint. 1 In LIFE patients NOD could be predicted by a risk score using significant variables from multivariate analyses, including serum glucose concentration, body mass index (BMI), serum HDL cholesterol concentration, systolic blood pressure (SBP) and prior use of antihypertensive drugs. Univariate analyses also showed a relation between serum uric acid (SUA) and risk of new-onset diabetes. 2 In the same population baseline SUA was significantly associated with increased rate of the composite outcome of CV death, nonfatal myocardial infarction, or nonfatal stroke, especially in women, 3, 4 and with new-onset atrial fibrillation. 5 SUA increased most in the group receiving atenolol. Losartan competes with the reabsorption of uric acid in the tubules and thereby leads to increased uric acid excretion by the kidneys, which may explain this difference. 3 The association of hyperuricemia with hyperglycemia was first described by Kylin. 6 In recent years the association of SUA with diabetes has been studied in different ethnic groups.
According to these studies, it is not settled to what extent SUA independently predicts the development of diabetes. 7 Whereas it was suggested that SUA is an independent risk factor for diabetes in the Rotterdam study, a cohort study of 4536 healthy subjects free from diabetes at baseline, aged 55 years and older, [8] [9] [10] it has previously not been investigated whether SUA is associated with the development of NOD in patients with hypertension and left ventricular hypertrophy (LVH), a population with particular high risk of developing diabetes 2 and in which SUA predicts major cardiovascular disease. 3 Thus, the aim of the present investigation 4 was to test our hypothesis 2 that SUA predicts development of NOD in hypertensive patients with LVH.
Methods

Participants:
The LIFE study population consists of 9193 patients aged 55 to 80 with previously untreated or treated essential hypertension and ECG-LVH, by Cornell voltageduration product or Sokolow-Lyon voltage. 11 The LIFE study included patients with mean trough sitting diastolic BP of 95-115 mmHg and/or a mean sitting systolic BP of 160-200 mmHg after 1-2 weeks on single-blind placebo treatment, who had not suffered a myocardial infarction or stroke within 6 months, and did not have known LV ejection fraction < 40%, or required treatment with a β-blocker, angiotensin converting enzyme-(ACE)-inhibitor, or angiotensin receptor-(AT 1 )-antagonist. The mean age at inclusion was 66.9 years, 54.1% were women, and the mean baseline BP was 174.4/97.8 mmHg.
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Of the 9193 patients participating in the LIFE study, 1195 patients with diabetes mellitus at study baseline were excluded from the current analysis, leaving 7998 patients who were at risk of developing diabetes to be included in the present study. However, 509 patients did not have their SUA measured at baseline. These patients were excluded, leaving 7489 to be included in the statistical analyses. They were quite similar to the rather few patients who did not have SUA at baseline except for small differences in baseline DBP (98.0 vs. 98.9 mmHg, P = 0.02) and ISH status (13.8 vs. 10.2 %, P = 0.02).
If a patient who did not have diabetes at baseline had a non-fasting serum glucose concentration of 144 mg/dl or more, further investigations were made (including repeated fasting glucose or an oral glucose tolerance test, or both). 2 New-onset diabetes mellitus was defined in the LIFE study according to the 1985 World Health Organization (WHO) criteria. Once diabetes was determined to be present on the basis of this definition, the investigator 5 entered the information into the database. New recommendations for diagnosing NIDDM, mainly using fasting glucose of 126 mg/dl or more, were published by WHO in 1999 while the study was still in progress. 2 Study protocol was not changed, and 1999 criteria was not advocated, but it was decided before the end of the study that all patients who were diagnosed with diabetes during the study would be included in the analyses regardless of the criteria (WHO 1985 or WHO 1999) upon which the diagnosis was based. The patients were followed for a mean of 4.9±0.8 years.
Procedures:
The LIFE study was a double-masked, randomized, parallel-group trial.
The primary objective was to evaluate the long-term effects of losartan-compared with atenolol-based antihypertensive therapy in patients with hypertension and ECG-LVH on the incidence of cardiovascular morbidity and mortality. 1 The LIFE study design, organization, clinical measures, endpoint definitions, basis for choice of comparative agents, statistical power calculations, recruitment details, baseline characteristics, 1-year follow-up, and primary results have been published. 1, [12] [13] The primary endpoint was a composite of cardiovascular death, non-fatal stroke, or non-fatal myocardial infarction. Other pre-specified outcome measures were components of the primary composite endpoint, total mortality, hospitalization for angina pectoris, hospitalization for heart failure, coronary or peripheral revascularization procedures, resuscitated cardiac arrest, and new-onset diabetes mellitus. 1 The trial protocol was approved by local ethics committees and performed in accordance with the Declaration of Helsinki. All participants gave their informed consent.
The study was overseen by an independent data and safety monitoring board. Variables that had a significant univariate effect or were considered as clinically relevant were maintained when multivariate models were developed. Impact of SUA was calculated in a Demographic and clinical characteristics of the patients in relationship to baseline quartiles of SUA are compared in Table 1 . There were significant differences between the quartiles of baseline SUA in age, gender, race, weight, height, BMI, diastolic blood pressure, pulse pressure, heart rate, hemoglobin, serum sodium, potassium, creatinine, eGFR, urinary albumin/creatinine ratio, total and HDL cholesterol, glucose, history of stroke, history of ischemic heart disease, alcohol and Framingham risk score. The groups were similar with respect to systolic blood pressure, Sokolow-Lyon voltage, Cornell voltage-duration product, smoking, physical exercise habits, TIA, peripheral vascular disease and chronic obstructive pulmonary disorder (COPD).
During a mean follow-up of 4.9±0.8 years, new-onset diabetes mellitus developed in 522 patients (7%). There was a higher incidence of diabetes in higher quartiles of baseline SUA. The incidence of NOD rose from about 3% in the 1 st quartile of SUA at baseline to approximately 7% in the 2 nd and 3 rd quartiles of baseline SUA to nearly 11% in the 4 th quartile of baseline SUA (Figure 1 ). 8 The statistically significant univariate predictors of NOD were baseline and timevarying SUA, BMI, baseline Cornell product, creatinine, eGFR, Framingham risk score, glucose, exercise, HDL, heart rate, hemoglobin, potassium, pulse pressure, systolic blood pressure, total cholesterol, treatment (atenolol vs. losartan), weight, maximal dose of hydrochlorothiazide during study, time-varying Sokolow-Lyon and Cornell product, and timevarying diastolic blood pressure (Supplemental Table) .
The relation of SUA to the development of new-onset diabetes is examined further in In additional models using the main multivariate model and also adjusting for concomitant treatment with hydrochlorothiazide and/or baseline BMI and/or baseline HDL, the association of baseline SUA and baseline quartiles of SUA with NOD was still highly significant (Table 2) . When using the main multivariate model and also adjusting for concomitant treatment with hydrochlorothiazide, the association between time-varying SUA and NOD was no longer significant (HR 1.07, 95% CI 1.00-1.16, P = 0.066). Similarly, when using the main multivariate model and also adjusting for baseline HDL and BMI, the association between time-varying SUA and NOD was not significant (HR 1.03, 95% CI 0.95- Figure 2 ).
In the main multivariate model adjusting for study treatment with losartan vs. atenolol, 
Discussion
The present investigation demonstrates that SUA is associated with NOD in hypertensive patients with LVH, independent of other predictors of diabetes in the LIFE study. The associations were strong, both with regards to SUA levels at baseline, time-varying SUA, and SUA quartiles at baseline and quartiles at 1, 2, 3 and 4 years after baseline. Our findings in hypertensive patients with LVH are in agreement with findings in other populations.
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Relationship of diabetes to SUA levels
In our analyses we considered baseline SUA, baseline quartiles of SUA and time-varying SUA as predictors of NOD. We also compared the lowest quartile of baseline SUA with each of the others. Finally the highest quartile of SUA was compared to the three lowest quartiles at baseline and after 1, 2, 3 and 4 years, with respect to risk of NOD. In all these analyses, the results were clearly significant. Furthermore, a strength of our findings is that adjusting the analysis for study treatment with losartan vs. atenolol, baseline serum glucose, urinary albumin/creatinine ratio, eGFR and Framingham risk score, time-varying systolic and The reference range of SUA is between 2.0 and 7.0 mg/dl for men, and between 2.0 and 6.0 mg/dl for women. 14 The total population of this study had a mean value of 5.5 mg/dl at baseline, which is high normal. At year 4 the mean value was 6.1 mg/dl. The patients in the upper quartile of baseline SUA are hyperuremic on average, with mean value of 7.3 mg/dl, ranging from 6.4 to 11.9 mg/dl.
The analyses show an increasing association from baseline to year 1, and from year 2 to year 3. The association decreased from year 1 to year 2 and from year 3 to year 4 ( Figure   2 ). This is most likely due to random variation. As the power analyses of the LIFE study was based on the composite cardiovascular endpoint, and not on the endpoint of NOD, such 12 variations may appear due to limited statistical power when analyzed from one year to the next.
High SUA as a risk factor for diabetes has been a matter of discussion. Hyperuricemia has been considered to be a result of insulin resistance rather than its precursor. 9 A number of studies have reported significant associations between SUA levels and individual components of the metabolic syndrome, which increase the risk of atherosclerotic cardiovascular disease and type 2 diabetes. A study by Hyon et al indicated that the prevalence of the metabolic syndrome increased substantially with increasing levels of serum uric acid. 15 A study in rats
showed that fructose-induced hyperuricemia plays a pathogenic role in the metabolic syndrome, and it has been shown that SUA is associated with oxidative stress and production of tumor necrosis factor-α, which are both related to the development of diabetes. 9 Moreover, it has been shown that uric acid increases insulin resistance in animal models by inhibiting the bioavailability of nitric oxide, which is essential for insulinstimulated glucose uptake. 16 Uric acid may also contribute to the risk of diabetes mellitus by a direct cytotoxic effect on the pancreatic B-cells via its alloxan-like derivatives. 17 In our study we observed that uric acid could be related to the development of diabetes, and the above mentioned findings support high SUA as a possible risk factor of type 2 diabetes.
Limitations
The LIFE study population was of older age and mainly white ethnicity. Participants were derived from a high-risk population of hypertensive patients and the outcome should be interpreted in this context. The adoption of a 1999 WHO recommendation for diagnosing type 2 diabetes during the later part of the LIFE study, led the Steering Committee to accept patients with diabetes diagnosed according to either the 1999 and 1985 recommendations. Values are either mean ± SD or number (%) of subjects. 1 Main model also adjusted for maximum dose hydrochlorothiazide during study. 2 Main model also adjusted for baseline HDL. 3 Main model also adjusted for baseline BMI. 4 Main model also adjusted for baseline BMI and HDL. 5 Main model also adjusted for baseline BMI, HDL and maximum dose hydrochlorothiazide during study. 6 HR indicates the trend across the 4 SUA quartiles.
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